What Dithranol Treats: Main Uses and Benefits

Dithranol is a topical medication primarily used for the management of chronic plaque psoriasis. It has been a established therapeutic option for several decades, specifically valued for its ability to address the characteristic thickening and scaling of the skin associated with this condition.

Primary Uses

The application of dithranol is focused on localized areas of stable plaque psoriasis. It is typically utilized when other initial topical treatments have not provided sufficient results. The medication works by slowing down the excessive production of skin cells, which is the underlying cause of the raised, scaly patches (plaques) seen in psoriasis patients.

While its primary indication is plaque psoriasis, it is occasionally used in specialized clinical settings for other skin conditions characterized by abnormal skin cell growth, such as:

• Chronic plaque psoriasis: The most common application, targeting thick, well-defined areas of affected skin.
• Scalp psoriasis: Specific formulations may be used to treat thick scaling on the scalp.
• Alopecia areata: In some instances, it is used as a form of irritant therapy to stimulate hair regrowth, though this is less common than its use in psoriasis.

Benefits and Clinical Effects

Dithranol is noted for its high efficacy in inducing long-term remission. Unlike some other topical treatments, the improvements achieved with dithranol can often last for several months after the treatment course has concluded.

• Reduction in Skin Cell Proliferation: It effectively inhibits the rapid division of keratinocytes, helping the skin return to a more normal rate of renewal.
• Resolution of Plaques: Regular application leads to the thinning of psoriasis plaques and the eventual removal of silvery scales.
• Anti-inflammatory Action: It helps reduce the localized inflammation and redness in the treated areas.
• Lack of Systemic Absorption: When applied correctly to the skin, dithranol does not significantly enter the bloodstream, reducing the risk of internal side effects.
• No Steroid-Related Risks: As a non-steroidal treatment, it avoids the complications associated with long-term topical corticosteroid use, such as skin thinning (atrophy) or stretch marks.

Dithranol (Anthralin) eligibility is defined by specific population rules documented in official regulatory labeling.

Populations and Conditions Prohibited from Use

The medicine is formally contraindicated in specific groups and conditions:

• Patients with a known hypersensitivity to the active ingredient, Dithranol, or to any other component of the specific product formulation.
• Individuals with acute or pustular psoriasis, or those experiencing actively inflamed psoriatic eruptions. Use is restricted to chronic, stable plaque psoriasis.
• Application to sensitive anatomical sites, including the face, mucous membranes, or sensitive skin folds (intertriginous areas).

Age-Related and Conditional Eligibility Status

Category	Official Regulatory Status
Primary Eligible Group	Adults with chronic plaque psoriasis.
Pediatric Use	Safety and effectiveness have not been established for children under 12 years of age. Use is limited to adolescents 12 and older for specific indications.
Pregnancy	Conditional use; administration is restricted to situations where it is considered clearly needed.
Lactation (Nursing)	Caution should be exercised. Regulators note that it is unknown if the medicine is excreted in human milk, requiring consideration of discontinuing the drug or nursing.

Regulatory documents do not state explicit eligibility restrictions related to hepatic or renal impairment.

Official Interaction Profile

The interaction profile for Dithranol is primarily defined by minimal systemic absorption and specific local, topical constraints, according to official regulatory information. The most significant finding regarding systemic drug risk is the confirmation that Dithranol does not inhibit liver microsomal enzyme activity (CYP enzymes), which results in a formally reduced likelihood of adverse systemic drug-drug interactions.

Interaction-Related Restrictions

Regulatory documentation mandates several local and temporal constraints on co-administration:

• Prohibited Combinations: Dithranol must not be used concurrently with photosensitising medications, as this co-administration may enhance their photosensitising effects. The use of products containing propylene glycol is also restricted due to the risk of Dithranol being oxidized and chemically inactivated.
• Efficacy Modifiers: Preparations containing salicylic acid are documented to enhance the treatment effect, while concurrent application of topical substances such as coal tar, zinc oxide, or starch may diminish the therapeutic results.
• Absorption Constraint: Dithranol may increase the absorption of other substances applied to the same area of skin, representing a caution for co-administered topical agents.

Mandatory Timing-Based Rules

A critical temporal requirement is mandated for prior treatments: a minimum interval of one to two weeks must be observed between the cessation of long-term topical steroids and the initiation of Dithranol treatment. This separation rule is required to mitigate the risk of a psoriasis rebound phenomenon.

Connection to the Overall Interaction Profile

Official regulatory documents confirm the interaction structure is largely localized to the application site. The profile establishes the absence of systemic pharmacokinetic risk, focusing instead on defining strict temporal and co-administration rules for topical and photosensitising agents to maintain the drug’s stability and efficacy.

Suppression of Epidermal Cell Overgrowth

The primary mechanism of Dithranol involves acting as a reducing agent that generates Reactive Oxygen Species (ROS) and free radicals upon application. These highly reactive species target the cell's power structures, the mitochondria, disrupting their energy supply and inactivating key metabolic enzymes. This process leads directly to the inhibition of DNA synthesis and mitotic activity within the rapidly proliferating keratinocytes, resulting in the regulation of epidermal cell kinetics.

---

Modulation of Local Inflammatory Signaling

In parallel with its anti-proliferative action, Dithranol exerts an anti-inflammatory effect by modulating the local immune environment. The mechanism suppresses the production of several pro-inflammatory cytokines (e.g., IL-8 and IL-36) and reduces the capacity of immune cells, such as T-lymphocytes and neutrophils, to infiltrate the tissue. By dampening the inflammatory signaling loop and limiting the migration of these cells, the mechanism produces a decrease in localized immune system activity.

---

Mechanistic Constraints of Redox Action

The therapeutic mechanism relies on the non-specific redox chemistry that generates ROS, which acts on broad cellular targets. This inherent mechanism cannot be entirely decoupled from collateral biochemical activity on non-target cellular structures. This mechanistic constraint relates to the resulting local biochemical stress that is a characteristic of this mode of action.

The administration of Dithranol, also known as Anthralin, is limited to the topical route for dermatologic use, as the product is formulated into various forms, including creams, ointments, pastes, and shampoos. Concentrations typically range from 0.1% to 2% across the available formulations.

---

The core usage principle is Short Contact Therapy (SCT), a regimen where the medicine is applied for a brief, controlled duration rather than being left on continuously. Application to the lesions is generally performed once a day. The treatment protocol begins with a low initial concentration and a short contact time, usually 5 to 15 minutes. Standard protocols involve increasing both the product strength and the contact duration stepwise (titrated) until the desired response is noted.

---

Application typically requires the product to be used sparingly and only on the psoriatic lesions, with instructions to avoid sensitive areas such as the eyes, mucous membranes, face, neck, and skin folds. At the conclusion of the prescribed contact time, the product must be removed completely by washing or showering. For specific populations, such as adolescents aged 12 and older, a shampoo formulation may be applied to the scalp for 3 to 5 minutes, up to four times weekly, following defined label instructions. This protocol ensures the application is administered under defined procedural constraints.

Research evidence / Overview of studies for Dithranol

---

Evidence for Use in Chronic Plaque Psoriasis

Research exploring Dithranol was studied for the management of chronic plaque psoriasis, a condition characterized by periods of heightened symptoms such as persistent, raised skin patches. The types of studies conducted include Randomized Controlled Trials (RCTs) and systematic reviews, which often combine findings from multiple individual trials to provide a broader understanding.

These studies monitored outcomes related to physical discomfort and skin condition, primarily using the standardized scale known as the Psoriasis Area and Severity Index (PASI) score. This score is used in research exploring how symptoms change over time by quantifying differences in the amount of scaling, redness, and thickness of the skin. RCTs reported that when Dithranol was compared to a placebo, patterns were observed in the changes to standardized disease scores.

The evidence base was assigned a classification of High, indicating the existence of a large volume of Randomized Controlled Trials addressing the research. However, some regulatory documents have noted that the extensive clinical experience with Dithranol over many years often exceeds the amount of formal, modern documentation available from large-scale clinical trials.

---

Comparative Trials and Placebo Research

Research examined Dithranol in trials designed to assess its relative standing in symptom management. Controlled studies explored various delivery methods and regimens, such as short-contact therapy, which is relevant in trials assessing short-term or episodic symptom patterns.

Comparative studies examining Dithranol alongside agents such as Vitamin D analogues indicated findings that were mixed across these trials. Comparative evidence remains limited in some areas, particularly in modern comparisons against all topical options available. Furthermore, some studies monitor the outcomes of multi-agent regimens combining Dithranol with other treatments, such as UVB light therapy or topical corticosteroids.

Long-Term Studies and Follow-Up Data

Studies focusing on the long-term impact of Dithranol research examined how long the skin maintained its improved state after the therapy was studied for, often tracking patients to measure the duration of remission. The follow-up durations were limited in many core efficacy studies, typically spanning three to eight weeks. However, some trials included extended follow-up periods, with research describing relapse patterns observed in some studies lasting up to two years.

Key Studies & References

1. Psoriasis (chronic plaque) - A systematic review of treatments for severe psoriasis (Cochrane Review/NCBI)
2. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid (PubMed) - Follow-up and efficacy trial
3. Psoriasis clinical guideline - American Academy of Dermatology (AAD) - Context for topical therapies

Common questions about Dithranol (FAQ)

Q: What is Dithranol used for?

A: Dithranol is a topical medication primarily used to treat psoriasis, a common skin condition that causes cells to build up rapidly on the surface of the skin, forming thick, silvery scales and itchy, dry patches. It is often used for chronic plaque psoriasis.

Q: How does Dithranol work?

A: Dithranol is believed to work by inhibiting the excessive growth and multiplication of skin cells (keratinocytes) that characterize psoriasis. It also acts as an anti-inflammatory agent, helping to reduce the redness and thickness of psoriatic plaques.

Q: How long does it take for Dithranol to work?

A: The time it takes for Dithranol to show improvement can vary among individuals and depends on the severity of the psoriasis and the specific treatment regimen. Generally, noticeable improvements may be seen after several weeks of consistent use. Treatment is often continued until the affected skin patches are cleared.

Q: What is the proper way to apply Dithranol?

A: Dithranol is usually applied to the affected areas of the skin, avoiding contact with healthy skin and sensitive areas like the eyes, mouth, and genitals. It is typically applied as a short-contact therapy, meaning it is left on the skin for a short period (often 10–60 minutes) before being washed off thoroughly. Your doctor will provide specific instructions on the concentration and duration of application.

Q: What are the common side effects of Dithranol?

A: Common side effects include skin irritation, such as burning, redness, or itching, especially when starting treatment or using higher concentrations. Dithranol can also cause temporary purple or brown staining of the skin, hair, and clothing. This staining is generally reversible on the skin but may be permanent on fabrics. Proper application techniques and short-contact therapy are used to minimize side effects.

Q: Can Dithranol be used on the face or in skin folds?

A: Dithranol is generally not recommended for use on the face, groin, or other sensitive skin areas (like skin folds) due to the high risk of severe irritation and staining. If prescribed for areas near the face or folds, low concentrations and very brief contact times are used under strict medical supervision.

Storage and Disposal Information

Dithranol preparations must be stored under specific conditions to ensure stability and safety.

Storage Scope	Regulatory Requirement
Temperature	Store at controlled room temperature (20 C to 25 C), avoiding excessive heat.
Container Rule	Keep the container tightly closed or tightly capped to protect the contents.
Child Safety	The medicine must be stored out of the sight and reach of children.

For disposal, the product should not be simply thrown in the trash or flushed. Unused or expired dithranol should be discarded using an official drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (such as coffee grounds or dirt) and placed in a sealed container before disposal in the household trash. Personal information must be removed from the packaging before discarding it.